Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397778 | 1.00 | MEN1 (0.68) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL13590694 | 0.84 | ACACB (0.66) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL4390037 | 0.81 | KMT2A (0.60) | MEN1KMT2ALMNACYP3A4CYP2C19 | |
| SCHEMBL4390035 | 0.81 | KMT2A (0.60) | MEN1KMT2ALMNACYP3A4CYP2C19 | |
| SCHEMBL4400806 | 0.81 | GBA1 (0.66) | MEN1KMT2ASMN1; SMN2THRBALDH1A1 | |
| SCHEMBL4400809 | 0.81 | GBA1 (0.66) | MEN1KMT2ASMN1; SMN2THRBALDH1A1 | |
| SCHEMBL16054998 | 0.77 | NAMPT (0.58) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL14419600 | 0.76 | CCR8 (0.61) | MEN1KMT2ASMN1; SMN2LMNATP53 | |
| SCHEMBL4396117 | 0.76 | PDK1 (0.54) | MEN1KMT2ASMN1; SMN2LMNATHRB | |
| SCHEMBL4396124 | 0.76 | PDK1 (0.54) | MEN1KMT2ASMN1; SMN2LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | MEN1 4443/4885KMT2A 1754/4885SMN1; SMN2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.